The recent FDA-mandated box warning for all 6 approved CAR-T therapies on potential secondary malignancies gave a massive fright to […]
Read More Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, […]
Read More Small-cell lung cancer (SCLC) is a fatal disease with limited treatment options. Circulating tumor cells (CTCs) in liquid biopsy samples […]
Read More Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious […]
Read More According to the press release by AstraZeneca on February 19th, the use of Tagrisso (osimertinib) after chemoradiotherapy (CRT) in patients […]
Read More The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; […]
Read More Colorectal cancer (CRC) is the 4th most common cause of new cancer diagnosis and the 2nd leading cause of cancer-related […]
Read More Radium-223 improves overall survival (OS) and reduces skeletal events in patients with bone metastatic castration-resistant prostate cancer (CRPC), but relevant […]
Read More The primary joint efficacy analysis of the Anthracyclines in Early Breast Cancer (ABC) trials reported in 2017, failed to demonstrate […]
Read More For patients with advanced-stage, unresectable or metastatic melanoma who have relapsed on prior systemic therapy, including a PD-1 blocking antibody […]
Read MoreError: Contact form not found.
